Regeneron announces retirement of board chair

Regeneron Pharmaceuticals (REGN) announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company’s Board of Directors and will not stand for reelection at the Company’s 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard Schleifer, M.D., Ph.D., and George Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively. The Board also plans to appoint current director Christine Poon as the Lead Independent Director of the Board. Dr. Schleifer served as Chair before Dr. Vagelos joined the Company. Dr. Vagelos is the former President, Chief Executive Officer, and Chair of the Board of Merck & Co. (MRK), and is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. Dr. Vagelos earned his Bachelor of Science degree in chemistry from the College of Arts and Sciences at the University of Pennsylvania and attended medical school at the Columbia University School of Medicine.